How to Actually Find (and Vet) Drug Discovery Grants Before You Apply

Ask most founders how their funding search is going and they'll tell you about a monolithic spreadsheet. Forty rows, maybe more, pulled from a database, a newsletter, a well-meaning LinkedIn post. What they rarely have is a shortlist. Discovery and validation get treated as the same task, done once, at the start. They're not the same task, and skipping the second one is how three good weeks disappear into an application that was probably never the one.

Discovery Is Not the Hard Part

Finding drug discovery grants isn't actually difficult. There are databases, government portals, sector newsletters, and funder websites, and between them they'll surface most of what's technically open. The problem is that "technically open" and "actually winnable" are different things, and a database has no way of telling you which entries on it are worth your most precious resource, your time.

Real discovery means going past the listing to the source. Read the funder's actual strategy document, not just their current call, because strategies tell you what they'll fund next year as well as this one. Look at who they've funded before, not just what they say they fund, because a funder's portfolio is a far more honest signal than their marketing copy. And pay attention to what a fund doesn't mention. A drug discovery grant that never references delivery mechanisms, formulation, or manufacturing scale-up almost certainly won't fund a project built around one of those things, whatever the eligibility page implies.

Validation Is the Part Everyone Skips

Once you've got a shortlist, the real work starts, and it's where most pipelines fall apart. Validation means testing each opportunity against your actual project before you write a word of the application, not after.

Start with precedent. Has this funder actually funded something like yours before, in this disease area, at this stage, at roughly this amount? A fund that's only ever backed platform technologies is unlikely to be the right home for a single asset, however well it fits on paper. Check the call is genuinely live, not just indexed. Databases lag, funders quietly close rounds early, and a deadline three months out can turn out to already be exhausted.

Then check the money against the work. A £50,000 award attached to an eighteen-month discovery programme is not a mismatch you can write your way around, it's a funder telling you they expect something smaller than what you're building. And check the timeline against your own. If the fund expects results within twelve months and your work genuinely needs eighteen, that's not a detail to iron out later, it's a reason this fund isn't yours yet, however good the fit looks otherwise.

A Small Test Worth Running

Before committing time to any drug discovery grant, try to write a single sentence: this funder has previously backed [something like your work], in [your disease area or mechanism type], at [roughly your stage], for [roughly your amount]. If you can't fill in all four blanks with something true, you don't have a validated opportunity yet.

Four Questions to Run Before You Commit

1. Has this funder backed something comparable before, not just something adjacent?
2. Is the call definitely still open, and have I checked the funder's own site rather than trusting the database date?
3. Does the award size match the scope of what I'm proposing, roughly, not optimistically?
4. Can I deliver inside their timeline without cutting corners I'd regret?

A no anywhere on this list doesn't mean the opportunity is worthless. It means it goes back in the pipeline for later.

How Ailsa Helps

This is exactly where Ailsa earns its keep. Instead of handing you a long list scraped from public databases, Ailsa checks each drug discovery grant against funder strategy, funding history, and your actual project details, so what reaches you has already cleared the validation step, not just the discovery one. Then an expert human writer helps you build the case properly. Less time vetting a spreadsheet. More time on the applications that are already worth writing. Book a demo at ailsa.io.